uniQure (NASDAQ:QURE) Earns “Outperform” Rating from Royal Bank of Canada

Royal Bank of Canada reaffirmed their outperform rating on shares of uniQure (NASDAQ:QURE) in a research report sent to investors on Tuesday,Benzinga reports. Royal Bank of Canada currently has a $24.00 target price on the biotechnology company’s stock.

QURE has been the subject of a number of other research reports. Guggenheim reiterated a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of uniQure in a report on Tuesday, December 10th. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Wednesday, December 11th. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their price target for the stock from $20.00 to $52.00 in a research note on Tuesday, December 10th. Finally, Leerink Partners raised their price objective on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.38.

uniQure Stock Up 3.5 %

uniQure stock opened at $15.83 on Tuesday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a one year low of $3.73 and a one year high of $19.18. The company has a 50-day simple moving average of $12.56 and a 200-day simple moving average of $8.61. The firm has a market capitalization of $771.55 million, a P/E ratio of -3.19 and a beta of 0.41.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, equities analysts expect that uniQure will post -3.74 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.74% of the stock is currently owned by insiders.

Institutional Investors Weigh In On uniQure

Hedge funds have recently modified their holdings of the stock. FNY Investment Advisers LLC purchased a new position in uniQure in the 4th quarter worth about $88,000. RTW Investments LP purchased a new position in shares of uniQure in the third quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,663 shares during the period. Atria Investments Inc purchased a new stake in shares of uniQure in the 3rd quarter valued at approximately $53,000. Finally, Quarry LP acquired a new position in uniQure in the 3rd quarter worth approximately $58,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.